Central Nervous System (CNS) Biomarker Market - By Biomarker Type: Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, Diagnostic Biomarkers; By Application: Drug Discovery & Development, Diagnostics, Disease Risk Assessment, Personalized Medicine, Clinical Trials Monitoring; By End User: Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Clinical Labs, Contract Research Organizations (CROs); By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
1 | Market Overview
The global central nervous system (CNS) biomarker market is growing quickly, driven by the increasing need for early diagnosis, targeted treatments, and effective disease monitoring of neurological disorders such as Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy. CNS biomarkers are essential in drug development, clinical trials, and diagnostics, providing insights into disease progression, treatment response, and prognosis.
Advancements in imaging technologies, genomics, proteomics, and fluid-based biomarker discovery drive market growth. The growing burden of neurodegenerative diseases, along with increased investment in precision medicine and neuroscience research, further accelerates demand.
2 | Market Size and Forecast
|
Year |
Market Value (USD Billion) |
Notes |
|
2019 |
4.92 |
Historical benchmark |
|
2024 |
7.93 |
Five-year CAGR 10.1% |
|
2031 |
17.89 |
Seven-year CAGR 12.3% |
The market is expected to more than double by 2031, fueled by demand for early diagnostics, precision neurology, and biomarker-driven clinical trials.
3 | Key Market Drivers
4 | Market Challenges
5 | Competitive Landscape
The CNS biomarker market is somewhat consolidated, with leading companies concentrating on biomarker assays, imaging diagnostics, and neurodegenerative disease research.
Market Share Estimates (2024):
|
Company |
Estimated Market Share |
Key Offerings |
|
Thermo Fisher Scientific |
20% |
Immunoassays, proteomics tools, genomics biomarkers |
|
Bio-Rad Laboratories |
17% |
Multiplex assays, neurodegeneration biomarker kits |
|
Merck KGaA (MilliporeSigma) |
15% |
Neurology ELISAs, proteomics reagents |
|
PerkinElmer Inc. |
12% |
Imaging biomarkers, CNS assay solutions |
|
Others (QIAGEN, Abcam, Roche Diagnostics, regional OEMs) |
36% |
Specialized assays, imaging, and omics-based biomarkers |
6 | Market Segmentation
By Biomarker Type:
By Application:
By End User:
By Region:
7 | Strategic Outlook
Future growth in the CNS biomarker market will be driven by AI-powered biomarker discovery, liquid biopsy development for neurological conditions, and multiplex imaging biomarkers. Collaborations between pharmaceutical companies and academic research centers will speed up biomarker translation from research to clinical use.
Need help?
Chat with our team in a minute.